in the absence of a submission from the holder of the marketing authorisation:
ramucirumab (Cyramza®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice357KB (PDF)
- Medicine name:
- ramucirumab (Cyramza)
- SMC ID:
- Pharmaceutical company
- Eli Lilly and Company Ltd
- Submission type
- Non submission
- Not recommended
- Date advice published
- 11 November 2019